- New preclinical data being presented by Idera (IDRA) demonstrates the ability of the company's IMO-8400 drug to "inhibit the survival and proliferation of B-cell lymphoma cells harboring the oncogenic MYD88 L265P genetic mutation."
- Idera has opened enrollment for a Phase 1/2 trial to evaluate IMO-8400 for use in treating " patients with Waldenströms macroglobulinemia who are refractory to prior therapies," and expects patient treatment to start in Q2.
- The company has also submitted a request to the FDA to "conduct a Phase 1/2 trial in patients with [diffuse large B-cell lymphoma] who harbor the MYD88 L265P mutation."
From other sites
ETF Screener: Search and filter by asset class, strategy, theme, performance, yield, and much more
ETF Performance: View ETF performance across key asset classes and investing themes
ETF Investing Guide: Learn how to build and manage a well-diversified, low cost ETF portfolio
ETF Selector: An explanation of how to select and use ETFs